Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (30)
Koji Tsutsumi, Ayumi Nohara, Taiki Tanaka, Moe Murano, Yurina Miyagaki & Yasutaka Ohta. (2023) FilGAP regulates tumor growth in Glioma through the regulation of mTORC1 and mTORC2. Scientific Reports 13:1.
Crossref
Crossref
Jingru Qiu, Qinghong Liu, Peixia Li, Qiaoyun Jiang, Weijia Chen, Donghai Li, Guiling Li & Gang Shan. (2023) Ligand-Directed Photodegradation of Interacting Proteins: Oxidative HER2/HER3 Heterodimer Degradation with a Lapatinib-Derived Photosensitizer. Journal of Medicinal Chemistry 66:15, pages 10265-10272.
Crossref
Crossref
Roja Sahu, Shivesh Jha & Shakti P. Pattanayak. (2023) Suppression of mTOR Expression by siRNA Leads to Cell Cycle Arrest
and Apoptosis Induction in MDA-MB-231 Breast Cancer Cells. Current Gene Therapy 23:3, pages 228-242.
Crossref
Crossref
Abdelhakim Bouyahya, Aicha El Allam, Sara Aboulaghras, Saad Bakrim, Naoual El Menyiy, Mohammed Merae Alshahrani, Ahmed Abdullah Al Awadh, Taoufiq Benali, Learn-Han Lee, Nasreddine El Omari, Khang Wen Goh, Long Chiau Ming & Mohammad S. Mubarak. (2022) Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and Immunotherapy. Cancers 14:22, pages 5520.
Crossref
Crossref
Arun Pandian Chandrasekaran, Apoorvi Tyagi, Naresh Poondla, Neha Sarodaya, Janardhan Keshav Karapurkar, Kamini Kaushal, Chang-Hwan Park, Seok-Ho Hong, Kye-Seong Kim & Suresh Ramakrishna. (2022) Dual role of deubiquitinating enzyme USP19 regulates mitotic progression and tumorigenesis by stabilizing survivin. Molecular Therapy 30:11, pages 3414-3429.
Crossref
Crossref
Pian Yu, Shifu Luo, Jiaxin Cai, Jie Li & Cong Peng. (2022) ERAP2 as a potential biomarker for predicting gemcitabine response in patients with pancreatic cancer. Aging 14:19, pages 7941-7958.
Crossref
Crossref
Chewei Anderson Chang, Jayu Jen, Shaowen Jiang, Azin Sayad, Arvind Singh Mer, Kevin R. Brown, Allison M.L. Nixon, Avantika Dhabaria, Kwan Ho Tang, David Venet, Christos Sotiriou, Jiehui Deng, Kwok-kin Wong, Sylvia Adams, Peter Meyn, Adriana Heguy, Jane A. Skok, Aristotelis Tsirigos, Beatrix Ueberheide, Jason Moffat, Abhyudai Singh, Benjamin Haibe-Kains, Alireza Khodadadi-Jamayran & Benjamin G. Neel. (2022) Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer. Cancer Discovery 12:4, pages 1022-1045.
Crossref
Crossref
Stefania Crucitta, Federico Cucchiara, Francesca Sciandra, Annalisa Cerbioni, Lucrezia Diodati, Concetta Rafaniello, Annalisa Capuano, Andrea Fontana, Stefano Fogli, Romano Danesi & Marzia Del Re. (2022) Pharmacological Basis of Breast Cancer Resistance to Therapies - An Overview. Anti-Cancer Agents in Medicinal Chemistry 22:4, pages 760-774.
Crossref
Crossref
Mary Luz Uribe, Ilaria Marrocco & Yosef Yarden. (2021) EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. Cancers 13:11, pages 2748.
Crossref
Crossref
Chao Dong, Jiao Wu, Yin Chen, Jianyun Nie & Ceshi Chen. (2021) Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer. Frontiers in Pharmacology 12.
Crossref
Crossref
A. Geneste, M. N. Duong, L. Molina, L. Conilh, S. Beaumel, A. Cleret, K. Chettab, M. Lachat, L. P. Jordheim, E. L. Matera & C. Dumontet. (2020) Adipocyte-conditioned medium induces resistance of breast cancer cells to lapatinib. BMC Pharmacology and Toxicology 21:1.
Crossref
Crossref
Roja Sahu & Shakti P. Pattanayak. (2020) Strategic Developments & Future Perspective on Gene Therapy for Breast Cancer: Role of mTOR and Brk/ PTK6 as Molecular Targets. Current Gene Therapy 20:4, pages 237-258.
Crossref
Crossref
S. Wang, M. Gu, H. Jiang & X. Zheng. (2019) BMP-2 upregulates the AKT/mTOR pathway in breast cancer with microcalcification and indicates a poor prognosis. Clinical and Translational Oncology 22:8, pages 1263-1271.
Crossref
Crossref
Ioannis K. Zervantonakis, Matthew D. Poskus, Alexis L. Scott, Laura M. Selfors, Jia-Ren Lin, Deborah A. DillonShailja Pathania, Peter K. SorgerGordon B. Mills & Joan S. Brugge. (2020) Fibroblast–tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and antiapoptotic pathways. Proceedings of the National Academy of Sciences 117:28, pages 16500-16508.
Crossref
Crossref
Shannon Lee, Jens Rauch & Walter Kolch. (2020) Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity. International Journal of Molecular Sciences 21:3, pages 1102.
Crossref
Crossref
Vidyalakshmi Sethunath, Huizhong Hu, Carmine De Angelis, Jamunarani Veeraraghavan, Lanfang Qin, Nicholas Wang, Lukas M. Simon, Tao Wang, Xiaoyong Fu, Agostina Nardone, Resel Pereira, Sarmistha Nanda, Obi L. Griffith, Anna Tsimelzon, Chad Shaw, Gary C. Chamness, Jorge S. Reis-Filho, Britta Weigelt, Laura M. Heiser, Susan G. Hilsenbeck, Shixia Huang, Mothaffar F. Rimawi, Joe W. Gray, C. Kent Osborne & Rachel Schiff. (2019) Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment
Resistance in Breast Cancer. Molecular Cancer Research 17:11, pages 2318-2330.
Crossref
Crossref
Claudio Vernieri, Monica Milano, Marta Brambilla, Alessia Mennitto, Claudia Maggi, Maria Silvia Cona, Michele Prisciandaro, Chiara Fabbroni, Luigi Celio, Gabriella Mariani, Giulia Valeria Bianchi, Giuseppe Capri & Filippo de Braud. (2019) Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives. Critical Reviews in Oncology/Hematology 139, pages 53-66.
Crossref
Crossref
Oro Uchenunu, Michael Pollak, Ivan Topisirovic & Laura Hulea. (2019) Oncogenic kinases and perturbations in protein synthesis machinery and energetics in neoplasia. Journal of Molecular Endocrinology 62:2, pages R83-R103.
Crossref
Crossref
Jennifer A. Woyach. 2019. Precision Cancer Medicine. Precision Cancer Medicine
65
82
.
Yoojin Chang, Kyong Hwa Park, Ji Eun Lee & Ki-Cheol Han. (2018) Phosphoproteomic analysis reveals PAK2 as a therapeutic target for lapatinib resistance in HER2-positive breast cancer cells. Biochemical and Biophysical Research Communications 505:1, pages 187-193.
Crossref
Crossref
Gabrielle Karpinsky, Malgorzata A. Krawczyk, Ewa Izycka-Swieszewska, Aleksandra Fatyga, Agnieszka Budka, Walentyna Balwierz, Grazyna Sobol, Beata Zalewska-Szewczyk, Magdalena Rychlowska-Pruszynska, Teresa Klepacka, Bozenna Dembowska-Baginska, Bernarda Kazanowska, Anna Gabrych & Ewa Bien. (2018) Tumor expression of survivin, p53, cyclin D1, osteopontin and fibronectin in predicting the response to neo-adjuvant chemotherapy in children with advanced malignant peripheral nerve sheath tumor. Journal of Cancer Research and Clinical Oncology 144:3, pages 519-529.
Crossref
Crossref
Ming Zhao, Erin W. Howard, Amanda B. Parris, Zhiying Guo, Qingxia Zhao, Zhikun Ma, Ying Xing, Bolin Liu, Susan M. Edgerton, Ann D. Thor & Xiaohe Yang. (2017) Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells. Oncotarget 8:35, pages 58847-58864.
Crossref
Crossref
Jia Liu, Hui-Qing Li, Fu-Xia Zhou, Jie-Wen Yu, Ling Sun & Zhong-Hou Han. (2017) Targeting the mTOR pathway in breast cancer. Tumor Biology 39:6, pages 101042831771082.
Crossref
Crossref
Dirk Theile, Gal Lenz, Jamil A. Momand & Susan E. Kane. 2017. Resistance to Targeted Therapies in Breast Cancer. Resistance to Targeted Therapies in Breast Cancer
35
88
.
Huiping Shi, Weili Zhang, Qiaoming Zhi & Min Jiang. (2016) Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms. Tumor Biology 37:12, pages 15411-15431.
Crossref
Crossref
Giancarlo Pruneri, Giuseppina Bonizzi & Andrea Vingiani. (2016) Biomarkers for the identification of recurrence in human epidermal growth factor receptor 2-positive breast cancer patients. Current Opinion in Oncology 28:6, pages 476-483.
Crossref
Crossref
Ben Davidson, Kristin Valborg Reinertsen, Don Trinh, Wenche Reed & Per Johannes Bøhler. (2016) BAG-1/SODD, HSP70, and HSP90 are potential prognostic markers of poor survival in node-negative breast carcinoma. Human Pathology 54, pages 64-73.
Crossref
Crossref
Young-Hoon Park, Mi Suk Jeong & Se Bok Jang. (2016) Functional and Physiological Characteristic of RIPK and MLKL in TNF Signaling. Journal of Life Science 26:7, pages 868-874.
Crossref
Crossref
Valentina D?Amato, Lucia Raimondo, Luigi Formisano, Mario Giuliano, Sabino De Placido, Roberta Rosa & Roberto Bianco. (2015) Mechanisms of lapatinib resistance in HER2-driven breast cancer. Cancer Treatment Reviews 41:10, pages 877-883.
Crossref
Crossref
Harvey Schwartz, Brad Scroggins, Abbey Zuehlke, Toshiki Kijima, Kristin Beebe, Alok Mishra, Len Neckers & Thomas Prince. (2015) Combined HSP90 and kinase inhibitor therapy: Insights from The Cancer Genome Atlas. Cell Stress and Chaperones 20:5, pages 729-741.
Crossref
Crossref